| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 75 | 2024 | 4139 | 5.770 |
Why?
|
| Thyroid Neoplasms | 42 | 2024 | 1884 | 4.660 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 20 | 2024 | 273 | 4.300 |
Why?
|
| Mouth Neoplasms | 16 | 2024 | 734 | 3.960 |
Why?
|
| Oropharyngeal Neoplasms | 32 | 2024 | 1161 | 3.250 |
Why?
|
| Carcinoma, Squamous Cell | 47 | 2023 | 5606 | 2.880 |
Why?
|
| Osteoradionecrosis | 10 | 2024 | 128 | 2.040 |
Why?
|
| Deglutition Disorders | 17 | 2022 | 489 | 1.640 |
Why?
|
| Surgical Oncology | 5 | 2024 | 208 | 1.530 |
Why?
|
| Magnetic Resonance Imaging | 24 | 2024 | 7916 | 1.470 |
Why?
|
| Mandible | 9 | 2024 | 190 | 1.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 7 | 2024 | 1453 | 1.190 |
Why?
|
| Pyruvic Acid | 10 | 2021 | 132 | 1.170 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 632 | 1.120 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 708 | 1.110 |
Why?
|
| Mandibular Diseases | 4 | 2024 | 49 | 1.050 |
Why?
|
| Neck Dissection | 9 | 2024 | 294 | 1.050 |
Why?
|
| Lactic Acid | 5 | 2018 | 310 | 1.040 |
Why?
|
| Salivary Gland Neoplasms | 6 | 2018 | 499 | 1.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 15 | 2022 | 2164 | 1.000 |
Why?
|
| ErbB Receptors | 6 | 2015 | 2380 | 0.980 |
Why?
|
| Humans | 211 | 2024 | 271550 | 0.940 |
Why?
|
| Thyroidectomy | 9 | 2020 | 492 | 0.940 |
Why?
|
| Carcinoma | 12 | 2022 | 2621 | 0.930 |
Why?
|
| Carbon Isotopes | 5 | 2021 | 364 | 0.880 |
Why?
|
| Medical Marijuana | 1 | 2023 | 25 | 0.850 |
Why?
|
| Cannabidiol | 1 | 2023 | 43 | 0.840 |
Why?
|
| Hallucinogens | 1 | 2023 | 48 | 0.830 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2021 | 3908 | 0.820 |
Why?
|
| Cannabis | 1 | 2023 | 70 | 0.810 |
Why?
|
| MicroRNAs | 5 | 2020 | 2902 | 0.800 |
Why?
|
| Pandemics | 5 | 2020 | 1604 | 0.800 |
Why?
|
| Xerostomia | 3 | 2022 | 204 | 0.790 |
Why?
|
| Radiopharmaceuticals | 8 | 2019 | 1338 | 0.790 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14631 | 0.770 |
Why?
|
| Contrast Media | 5 | 2022 | 1504 | 0.720 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 316 | 0.710 |
Why?
|
| Erythropoietin | 7 | 2016 | 215 | 0.710 |
Why?
|
| Male | 110 | 2024 | 128724 | 0.700 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 206 | 0.700 |
Why?
|
| Neoplasm Staging | 28 | 2023 | 14015 | 0.700 |
Why?
|
| Cell Line, Tumor | 26 | 2023 | 14818 | 0.690 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2024 | 131 | 0.670 |
Why?
|
| Laryngeal Neoplasms | 6 | 2019 | 533 | 0.670 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2022 | 1697 | 0.660 |
Why?
|
| Female | 108 | 2024 | 149106 | 0.660 |
Why?
|
| Receptors, Erythropoietin | 10 | 2016 | 76 | 0.650 |
Why?
|
| Deglutition | 7 | 2022 | 187 | 0.650 |
Why?
|
| Radiation Injuries | 9 | 2020 | 1470 | 0.630 |
Why?
|
| Cranial Nerve Diseases | 4 | 2021 | 77 | 0.620 |
Why?
|
| Neoplasm Invasiveness | 16 | 2020 | 4061 | 0.610 |
Why?
|
| Middle Aged | 82 | 2024 | 90422 | 0.590 |
Why?
|
| Enteral Nutrition | 5 | 2024 | 345 | 0.590 |
Why?
|
| Mice, Nude | 17 | 2021 | 4348 | 0.580 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 10736 | 0.580 |
Why?
|
| Aged | 78 | 2024 | 73451 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 2422 | 0.550 |
Why?
|
| Proto-Oncogene Proteins B-raf | 9 | 2024 | 1329 | 0.550 |
Why?
|
| Patient Reported Outcome Measures | 10 | 2022 | 864 | 0.550 |
Why?
|
| Disease Models, Animal | 7 | 2021 | 7404 | 0.530 |
Why?
|
| Radiation Tolerance | 4 | 2016 | 636 | 0.520 |
Why?
|
| Niacinamide | 2 | 2014 | 428 | 0.520 |
Why?
|
| STAT3 Transcription Factor | 6 | 2016 | 1137 | 0.510 |
Why?
|
| Carcinoma, Papillary | 8 | 2015 | 580 | 0.510 |
Why?
|
| Sialadenitis | 1 | 2015 | 8 | 0.510 |
Why?
|
| Patient Care Planning | 2 | 2017 | 304 | 0.510 |
Why?
|
| Retrospective Studies | 55 | 2024 | 39818 | 0.510 |
Why?
|
| Cancer Survivors | 8 | 2022 | 744 | 0.510 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2015 | 13 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 9053 | 0.500 |
Why?
|
| Chemoradiotherapy | 10 | 2021 | 2028 | 0.500 |
Why?
|
| Salivary Ducts | 1 | 2015 | 55 | 0.490 |
Why?
|
| Mannans | 1 | 2015 | 31 | 0.490 |
Why?
|
| Dextrans | 1 | 2015 | 99 | 0.490 |
Why?
|
| Gastrostomy | 2 | 2013 | 195 | 0.470 |
Why?
|
| Lentivirus | 1 | 2015 | 164 | 0.470 |
Why?
|
| Virion | 1 | 2015 | 186 | 0.460 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 600 | 0.450 |
Why?
|
| Survival Analysis | 17 | 2023 | 9307 | 0.450 |
Why?
|
| Mice | 38 | 2022 | 35697 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 1899 | 0.450 |
Why?
|
| Signal Transduction | 18 | 2015 | 12134 | 0.440 |
Why?
|
| Prospective Studies | 22 | 2024 | 13385 | 0.440 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2024 | 4961 | 0.440 |
Why?
|
| Lymph Nodes | 6 | 2023 | 3079 | 0.440 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2020 | 3675 | 0.440 |
Why?
|
| Animals | 46 | 2024 | 62359 | 0.430 |
Why?
|
| Organ Sparing Treatments | 3 | 2019 | 280 | 0.430 |
Why?
|
| Quality of Life | 11 | 2024 | 4764 | 0.430 |
Why?
|
| Adult | 58 | 2024 | 82003 | 0.430 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2019 | 2274 | 0.420 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2013 | 84 | 0.420 |
Why?
|
| Plasmids | 1 | 2015 | 939 | 0.420 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1740 | 0.410 |
Why?
|
| Milk Proteins | 6 | 2005 | 127 | 0.410 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2016 | 606 | 0.410 |
Why?
|
| Lymphatic Metastasis | 8 | 2024 | 4965 | 0.400 |
Why?
|
| Tumor Burden | 9 | 2018 | 2034 | 0.400 |
Why?
|
| Deoxyglucose | 1 | 2012 | 122 | 0.400 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2010 | 57 | 0.390 |
Why?
|
| Positron-Emission Tomography | 12 | 2022 | 2199 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 2390 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1317 | 0.380 |
Why?
|
| Parotid Gland | 2 | 2020 | 116 | 0.380 |
Why?
|
| Neoplasm Metastasis | 5 | 2018 | 5315 | 0.370 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 31066 | 0.370 |
Why?
|
| Alveolar Process | 1 | 2010 | 10 | 0.370 |
Why?
|
| Jaw Diseases | 1 | 2010 | 20 | 0.360 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2008 | 141 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2023 | 10370 | 0.360 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2010 | 39 | 0.360 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2024 | 90 | 0.360 |
Why?
|
| Thyroid Gland | 4 | 2018 | 369 | 0.350 |
Why?
|
| Palate, Hard | 1 | 2009 | 15 | 0.350 |
Why?
|
| Receptors, Interleukin | 4 | 2018 | 99 | 0.350 |
Why?
|
| Consensus | 4 | 2024 | 1115 | 0.350 |
Why?
|
| STAT Transcription Factors | 1 | 2010 | 80 | 0.350 |
Why?
|
| Salivary Glands, Minor | 1 | 2009 | 36 | 0.350 |
Why?
|
| Janus Kinases | 2 | 2013 | 175 | 0.350 |
Why?
|
| Phenotype | 1 | 2021 | 6493 | 0.350 |
Why?
|
| Triage | 3 | 2020 | 258 | 0.340 |
Why?
|
| Radiotherapy Dosage | 12 | 2024 | 3999 | 0.340 |
Why?
|
| Disease-Free Survival | 16 | 2020 | 10258 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 267 | 0.330 |
Why?
|
| DNA, Antisense | 1 | 2009 | 44 | 0.330 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2020 | 109 | 0.330 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2020 | 135 | 0.320 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 1008 | 0.320 |
Why?
|
| Treatment Outcome | 31 | 2024 | 33870 | 0.320 |
Why?
|
| Combined Modality Therapy | 17 | 2023 | 9049 | 0.320 |
Why?
|
| Video-Assisted Surgery | 1 | 2008 | 30 | 0.320 |
Why?
|
| Academic Medical Centers | 4 | 2019 | 689 | 0.320 |
Why?
|
| Vocal Cords | 2 | 2018 | 105 | 0.310 |
Why?
|
| Betacoronavirus | 4 | 2020 | 521 | 0.310 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2007 | 46 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 16646 | 0.300 |
Why?
|
| Thyroid Nodule | 1 | 2008 | 94 | 0.300 |
Why?
|
| Protein-Tyrosine Kinases | 10 | 2010 | 1839 | 0.300 |
Why?
|
| Cohort Studies | 16 | 2022 | 9477 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2020 | 5451 | 0.290 |
Why?
|
| Survival Rate | 13 | 2021 | 12528 | 0.290 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 84 | 0.290 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2007 | 110 | 0.290 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2024 | 341 | 0.280 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 533 | 0.280 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2022 | 2452 | 0.280 |
Why?
|
| Algorithms | 9 | 2022 | 3925 | 0.280 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 164 | 0.270 |
Why?
|
| Robotics | 1 | 2010 | 365 | 0.270 |
Why?
|
| Lymphedema | 2 | 2023 | 239 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 5224 | 0.270 |
Why?
|
| Survivors | 6 | 2023 | 1023 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 7 | 2021 | 5762 | 0.260 |
Why?
|
| Quinazolines | 1 | 2011 | 956 | 0.260 |
Why?
|
| Receptors, Interleukin-2 | 5 | 1996 | 195 | 0.260 |
Why?
|
| Neoplasms | 8 | 2017 | 15903 | 0.250 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2020 | 340 | 0.250 |
Why?
|
| Telomerase | 3 | 2019 | 547 | 0.250 |
Why?
|
| Blood Vessels | 2 | 2020 | 232 | 0.250 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 5099 | 0.250 |
Why?
|
| Piperidines | 1 | 2011 | 1087 | 0.250 |
Why?
|
| Immunity, Innate | 2 | 2020 | 690 | 0.250 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 4505 | 0.240 |
Why?
|
| Trans-Activators | 7 | 2005 | 1631 | 0.240 |
Why?
|
| Quality Improvement | 3 | 2017 | 919 | 0.240 |
Why?
|
| Mutation | 15 | 2024 | 15918 | 0.240 |
Why?
|
| United States | 10 | 2020 | 16006 | 0.240 |
Why?
|
| Unsupervised Machine Learning | 1 | 2024 | 20 | 0.230 |
Why?
|
| Cisplatin | 6 | 2023 | 2501 | 0.230 |
Why?
|
| Patient Selection | 3 | 2020 | 2033 | 0.230 |
Why?
|
| Feasibility Studies | 6 | 2021 | 2364 | 0.230 |
Why?
|
| Hypoglossal Nerve Diseases | 1 | 2023 | 6 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5407 | 0.230 |
Why?
|
| Risk Assessment | 10 | 2024 | 6845 | 0.230 |
Why?
|
| Radiation, Ionizing | 2 | 2015 | 190 | 0.230 |
Why?
|
| Translations | 1 | 2024 | 43 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2023 | 743 | 0.230 |
Why?
|
| Statistics, Nonparametric | 3 | 2020 | 989 | 0.230 |
Why?
|
| Tongue Neoplasms | 2 | 2020 | 253 | 0.220 |
Why?
|
| Disease Resistance | 1 | 2023 | 25 | 0.220 |
Why?
|
| Papillomavirus Infections | 3 | 2021 | 1016 | 0.220 |
Why?
|
| Cancer Care Facilities | 5 | 2020 | 908 | 0.220 |
Why?
|
| Lipedema | 1 | 2023 | 1 | 0.220 |
Why?
|
| Receptors, CCR5 | 1 | 2023 | 55 | 0.220 |
Why?
|
| Down-Regulation | 3 | 2021 | 2096 | 0.220 |
Why?
|
| Dose-Response Relationship, Radiation | 5 | 2019 | 751 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2017 | 1261 | 0.220 |
Why?
|
| Cell Proliferation | 7 | 2021 | 7259 | 0.220 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 174 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 7937 | 0.210 |
Why?
|
| Occupational Health | 2 | 2020 | 93 | 0.210 |
Why?
|
| Sphenoid Sinus | 1 | 2002 | 24 | 0.210 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2002 | 33 | 0.210 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 5936 | 0.210 |
Why?
|
| Exercise Therapy | 2 | 2017 | 293 | 0.210 |
Why?
|
| Facial Paralysis | 1 | 2022 | 58 | 0.210 |
Why?
|
| Young Adult | 16 | 2020 | 22190 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2005 | 2616 | 0.210 |
Why?
|
| Iodine Radioisotopes | 3 | 2024 | 387 | 0.210 |
Why?
|
| Receptors, Cytokine | 2 | 2010 | 179 | 0.210 |
Why?
|
| Registries | 4 | 2024 | 2223 | 0.200 |
Why?
|
| Encephalocele | 1 | 2002 | 59 | 0.200 |
Why?
|
| Tinnitus | 1 | 2022 | 39 | 0.200 |
Why?
|
| Carcinogenicity Tests | 1 | 2021 | 69 | 0.200 |
Why?
|
| Biosensing Techniques | 1 | 2002 | 82 | 0.200 |
Why?
|
| Tonsillar Neoplasms | 1 | 2022 | 81 | 0.200 |
Why?
|
| Oligonucleotides | 2 | 2015 | 243 | 0.200 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2021 | 10 | 0.190 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2013 | 303 | 0.190 |
Why?
|
| Antigens, CD | 2 | 1997 | 1429 | 0.190 |
Why?
|
| Fluorocarbons | 1 | 2022 | 63 | 0.190 |
Why?
|
| Radiotherapy | 5 | 2017 | 1861 | 0.190 |
Why?
|
| Models, Biological | 3 | 2017 | 3207 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 7 | 2011 | 226 | 0.190 |
Why?
|
| Voice Disorders | 1 | 2021 | 41 | 0.190 |
Why?
|
| Time Factors | 9 | 2020 | 13077 | 0.190 |
Why?
|
| Perforator Flap | 1 | 2022 | 96 | 0.190 |
Why?
|
| Granuloma, Laryngeal | 1 | 2000 | 1 | 0.190 |
Why?
|
| Aphonia | 1 | 2000 | 2 | 0.190 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 152 | 0.190 |
Why?
|
| Prognosis | 14 | 2021 | 22524 | 0.190 |
Why?
|
| Granuloma, Pyogenic | 1 | 2000 | 10 | 0.190 |
Why?
|
| Speech Disorders | 1 | 2021 | 85 | 0.190 |
Why?
|
| Airway Obstruction | 2 | 2001 | 272 | 0.190 |
Why?
|
| Respiratory Muscles | 2 | 2017 | 27 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2020 | 7792 | 0.180 |
Why?
|
| Laryngectomy | 3 | 2017 | 243 | 0.180 |
Why?
|
| Trismus | 1 | 2020 | 26 | 0.180 |
Why?
|
| Neck | 3 | 2015 | 394 | 0.180 |
Why?
|
| Hearing Loss | 1 | 2022 | 173 | 0.180 |
Why?
|
| Lymphoscintigraphy | 2 | 2023 | 35 | 0.180 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 4894 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2023 | 376 | 0.180 |
Why?
|
| Dissection | 1 | 2020 | 133 | 0.180 |
Why?
|
| Oropharynx | 2 | 2019 | 80 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 397 | 0.180 |
Why?
|
| CD4 Antigens | 1 | 2020 | 171 | 0.180 |
Why?
|
| Analgesics | 1 | 2023 | 409 | 0.170 |
Why?
|
| Muscle Strength | 2 | 2017 | 104 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 97 | 0.170 |
Why?
|
| Heart | 2 | 2020 | 1191 | 0.170 |
Why?
|
| Pharynx | 2 | 2020 | 150 | 0.170 |
Why?
|
| Ferrosoferric Oxide | 1 | 2020 | 39 | 0.170 |
Why?
|
| Pharyngeal Muscles | 2 | 2018 | 40 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2020 | 80 | 0.170 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 89 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2009 | 1378 | 0.170 |
Why?
|
| Ferric Compounds | 1 | 2020 | 77 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 1950 | 0.170 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 192 | 0.170 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 125 | 0.170 |
Why?
|
| DNA-Binding Proteins | 8 | 2005 | 5030 | 0.170 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2019 | 66 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 361 | 0.170 |
Why?
|
| Maxillofacial Injuries | 1 | 2019 | 12 | 0.160 |
Why?
|
| Apoptosis | 5 | 2021 | 7783 | 0.160 |
Why?
|
| Cyclobutanes | 1 | 2019 | 36 | 0.160 |
Why?
|
| Texas | 9 | 2021 | 6444 | 0.160 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 309 | 0.160 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2019 | 100 | 0.160 |
Why?
|
| Carboxylic Acids | 1 | 2019 | 58 | 0.160 |
Why?
|
| Clonal Evolution | 1 | 2021 | 251 | 0.160 |
Why?
|
| Immunohistochemistry | 6 | 2017 | 7790 | 0.160 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2020 | 507 | 0.160 |
Why?
|
| Glottis | 1 | 2019 | 68 | 0.160 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1554 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 175 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2019 | 498 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 158 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 1052 | 0.150 |
Why?
|
| Tyrosine | 7 | 2005 | 509 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 696 | 0.150 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 160 | 0.150 |
Why?
|
| Age Distribution | 2 | 2019 | 727 | 0.150 |
Why?
|
| Reference Values | 1 | 2020 | 1143 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 1081 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2002 | 408 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2024 | 6205 | 0.150 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 133 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 420 | 0.150 |
Why?
|
| Janus Kinase 2 | 4 | 2011 | 754 | 0.150 |
Why?
|
| Respiratory Aspiration | 1 | 2017 | 31 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2019 | 315 | 0.150 |
Why?
|
| Patient Safety | 2 | 2020 | 657 | 0.150 |
Why?
|
| Exhalation | 1 | 2017 | 61 | 0.150 |
Why?
|
| Wound Healing | 2 | 2020 | 761 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 261 | 0.150 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2024 | 340 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2020 | 611 | 0.140 |
Why?
|
| Metabolomics | 1 | 2021 | 505 | 0.140 |
Why?
|
| Radiotherapy, Conformal | 3 | 2019 | 898 | 0.140 |
Why?
|
| Proton Therapy | 2 | 2018 | 1635 | 0.140 |
Why?
|
| Carbon | 1 | 2018 | 164 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 3220 | 0.140 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.140 |
Why?
|
| Endoscopy | 2 | 2015 | 501 | 0.140 |
Why?
|
| Barium | 1 | 2016 | 29 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 2203 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2019 | 255 | 0.140 |
Why?
|
| Cough | 1 | 2017 | 126 | 0.140 |
Why?
|
| Genomics | 4 | 2024 | 2825 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2022 | 907 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2022 | 1935 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 2 | 2010 | 356 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 1997 | 111 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 482 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2021 | 558 | 0.130 |
Why?
|
| Naphthols | 1 | 2016 | 27 | 0.130 |
Why?
|
| Skull Base | 1 | 2017 | 226 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 250 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 15247 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2017 | 160 | 0.130 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2016 | 57 | 0.130 |
Why?
|
| Interleukin-4 | 1 | 1996 | 291 | 0.130 |
Why?
|
| X Chromosome | 1 | 1997 | 402 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 6264 | 0.130 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 125 | 0.130 |
Why?
|
| Transcriptome | 2 | 2023 | 1953 | 0.130 |
Why?
|
| Metabolism | 1 | 2015 | 50 | 0.130 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2015 | 44 | 0.130 |
Why?
|
| Copper Radioisotopes | 1 | 2015 | 31 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 649 | 0.130 |
Why?
|
| Glutaminase | 1 | 2016 | 70 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 276 | 0.120 |
Why?
|
| Glucose | 2 | 2023 | 1225 | 0.120 |
Why?
|
| Sulfides | 1 | 2015 | 49 | 0.120 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 20 | 0.120 |
Why?
|
| Mucus | 1 | 2015 | 109 | 0.120 |
Why?
|
| Symporters | 1 | 2015 | 104 | 0.120 |
Why?
|
| Thymidylate Synthase | 2 | 2011 | 57 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 286 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 289 | 0.120 |
Why?
|
| Heterografts | 2 | 2014 | 742 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 880 | 0.120 |
Why?
|
| Hematinics | 1 | 2016 | 109 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2015 | 295 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2016 | 2282 | 0.120 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 115 | 0.120 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2014 | 13 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1051 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 3988 | 0.120 |
Why?
|
| Photons | 1 | 2018 | 535 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 4337 | 0.120 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2016 | 232 | 0.120 |
Why?
|
| Copper | 1 | 2015 | 165 | 0.120 |
Why?
|
| Fluoresceins | 1 | 2014 | 74 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 247 | 0.110 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Age Factors | 3 | 2018 | 5502 | 0.110 |
Why?
|
| Risk Factors | 9 | 2022 | 17982 | 0.110 |
Why?
|
| Medical Audit | 1 | 2015 | 198 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 324 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 2078 | 0.110 |
Why?
|
| Specialties, Surgical | 1 | 2016 | 134 | 0.110 |
Why?
|
| Glycolysis | 2 | 2018 | 529 | 0.110 |
Why?
|
| Phosphorylation | 6 | 2013 | 4976 | 0.110 |
Why?
|
| src-Family Kinases | 2 | 2013 | 488 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 759 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 638 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 4153 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3022 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 335 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2018 | 1279 | 0.110 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 339 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 12032 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6234 | 0.110 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2021 | 127 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 337 | 0.110 |
Why?
|
| RNA, Messenger | 5 | 2016 | 6436 | 0.110 |
Why?
|
| Bone Diseases, Infectious | 1 | 2012 | 11 | 0.110 |
Why?
|
| Surgical Flaps | 3 | 2008 | 884 | 0.110 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2013 | 142 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 1445 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1401 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 876 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 196 | 0.110 |
Why?
|
| Mesenchymoma | 1 | 2012 | 14 | 0.110 |
Why?
|
| Osteomalacia | 1 | 2012 | 36 | 0.110 |
Why?
|
| Image Enhancement | 2 | 2016 | 554 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 694 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 327 | 0.100 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2012 | 18 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2015 | 823 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2324 | 0.100 |
Why?
|
| Transducers | 1 | 2012 | 57 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 4976 | 0.100 |
Why?
|
| Blotting, Western | 7 | 2016 | 3610 | 0.100 |
Why?
|
| Cell Division | 5 | 2012 | 2685 | 0.100 |
Why?
|
| Cetuximab | 4 | 2021 | 474 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2659 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 706 | 0.100 |
Why?
|
| Cell Survival | 3 | 2013 | 3068 | 0.100 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2013 | 146 | 0.100 |
Why?
|
| Etodolac | 1 | 2011 | 3 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 296 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2016 | 995 | 0.100 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 62 | 0.100 |
Why?
|
| Soft Tissue Infections | 1 | 2012 | 94 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 3347 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 114 | 0.100 |
Why?
|
| Biomarkers | 3 | 2023 | 5086 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 2670 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1147 | 0.100 |
Why?
|
| Genetic Therapy | 2 | 2010 | 1713 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2011 | 176 | 0.100 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 99 | 0.100 |
Why?
|
| Transfection | 3 | 2015 | 3130 | 0.100 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 235 | 0.100 |
Why?
|
| Cell Hypoxia | 3 | 2011 | 353 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2019 | 2123 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 643 | 0.090 |
Why?
|
| Kinetics | 5 | 2017 | 2228 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2011 | 751 | 0.090 |
Why?
|
| Janus Kinase 3 | 5 | 1998 | 47 | 0.090 |
Why?
|
| Eating | 1 | 2013 | 446 | 0.090 |
Why?
|
| Smoking | 1 | 2020 | 2549 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1750 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2011 | 60 | 0.090 |
Why?
|
| Eye Neoplasms | 1 | 2013 | 257 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 1180 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 613 | 0.090 |
Why?
|
| Probability | 2 | 2024 | 885 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 1722 | 0.090 |
Why?
|
| Taxoids | 2 | 2011 | 1007 | 0.090 |
Why?
|
| HIV Infections | 1 | 2023 | 2158 | 0.090 |
Why?
|
| Mustard Compounds | 1 | 2010 | 9 | 0.090 |
Why?
|
| Diphenylamine | 1 | 2010 | 16 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2010 | 366 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2011 | 247 | 0.090 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 168 | 0.090 |
Why?
|
| Phenylpropionates | 1 | 2010 | 17 | 0.090 |
Why?
|
| Bayes Theorem | 3 | 2021 | 1056 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1463 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3073 | 0.090 |
Why?
|
| Research Design | 1 | 2018 | 1574 | 0.090 |
Why?
|
| Enzyme Activation | 4 | 2005 | 1820 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2024 | 3547 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2015 | 465 | 0.090 |
Why?
|
| Incidence | 5 | 2021 | 5848 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 441 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 4380 | 0.090 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2011 | 115 | 0.090 |
Why?
|
| Adolescent | 8 | 2019 | 32726 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2015 | 585 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 619 | 0.090 |
Why?
|
| Binding Sites | 2 | 2013 | 2260 | 0.090 |
Why?
|
| Phantoms, Imaging | 4 | 2021 | 1330 | 0.090 |
Why?
|
| Maxilla | 1 | 2010 | 89 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 5082 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 700 | 0.090 |
Why?
|
| Anemia | 1 | 2016 | 728 | 0.090 |
Why?
|
| Fluorouracil | 2 | 2011 | 1989 | 0.090 |
Why?
|
| Interleukin-2 | 4 | 1998 | 889 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2017 | 1430 | 0.080 |
Why?
|
| Radiation Dosage | 3 | 2020 | 1046 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 1824 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4895 | 0.080 |
Why?
|
| Sulfonamides | 2 | 2016 | 1932 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2015 | 1859 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2023 | 2857 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2011 | 901 | 0.080 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 440 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 5771 | 0.080 |
Why?
|
| Pennsylvania | 1 | 2008 | 68 | 0.080 |
Why?
|
| Mouth Floor | 1 | 2008 | 14 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 268 | 0.080 |
Why?
|
| Mouth | 2 | 2020 | 125 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 1078 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 2359 | 0.080 |
Why?
|
| Radionuclide Imaging | 2 | 2023 | 657 | 0.080 |
Why?
|
| Mitochondria | 1 | 2015 | 1301 | 0.080 |
Why?
|
| Surgeons | 1 | 2015 | 487 | 0.080 |
Why?
|
| Base Sequence | 4 | 2011 | 5453 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 448 | 0.080 |
Why?
|
| Organs at Risk | 2 | 2024 | 559 | 0.080 |
Why?
|
| Mandibular Osteotomy | 2 | 2022 | 39 | 0.080 |
Why?
|
| Rabbits | 2 | 2020 | 1074 | 0.070 |
Why?
|
| Ischemia | 1 | 2011 | 407 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2008 | 103 | 0.070 |
Why?
|
| Structure-Activity Relationship | 4 | 1998 | 982 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 16221 | 0.070 |
Why?
|
| DNA Damage | 1 | 2015 | 1987 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2024 | 1071 | 0.070 |
Why?
|
| Larynx | 2 | 2020 | 144 | 0.070 |
Why?
|
| Disease Progression | 4 | 2015 | 6857 | 0.070 |
Why?
|
| GTPase-Activating Proteins | 1 | 2007 | 132 | 0.070 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2011 | 446 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 5163 | 0.070 |
Why?
|
| Ribonuclease III | 1 | 2008 | 188 | 0.070 |
Why?
|
| Melanoma | 2 | 2018 | 5598 | 0.070 |
Why?
|
| Oral Surgical Procedures | 1 | 2006 | 33 | 0.070 |
Why?
|
| HIV-1 | 2 | 2023 | 641 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1568 | 0.070 |
Why?
|
| Equipment Design | 3 | 2015 | 1199 | 0.070 |
Why?
|
| Comorbidity | 3 | 2022 | 2416 | 0.070 |
Why?
|
| Mandibular Neoplasms | 1 | 2006 | 77 | 0.070 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 2057 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 1442 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2022 | 646 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1458 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2010 | 1054 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 511 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2005 | 111 | 0.060 |
Why?
|
| Branchioma | 1 | 2004 | 3 | 0.060 |
Why?
|
| Earache | 1 | 2004 | 8 | 0.060 |
Why?
|
| Cell Line | 8 | 2004 | 5373 | 0.060 |
Why?
|
| Benzamides | 1 | 2010 | 1879 | 0.060 |
Why?
|
| Otolaryngology | 1 | 2006 | 141 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 792 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2005 | 116 | 0.060 |
Why?
|
| Myography | 1 | 2023 | 13 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1287 | 0.060 |
Why?
|
| Support Vector Machine | 1 | 2024 | 42 | 0.060 |
Why?
|
| Janus Kinase 1 | 4 | 1998 | 125 | 0.060 |
Why?
|
| Research | 1 | 2006 | 431 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 5185 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1586 | 0.060 |
Why?
|
| Tongue | 1 | 2023 | 85 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 584 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2023 | 101 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 686 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2009 | 1005 | 0.050 |
Why?
|
| Facial Nerve | 1 | 2022 | 58 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 368 | 0.050 |
Why?
|
| Remission Induction | 1 | 2009 | 3653 | 0.050 |
Why?
|
| Carboplatin | 2 | 2020 | 880 | 0.050 |
Why?
|
| Canada | 1 | 2024 | 441 | 0.050 |
Why?
|
| Motion | 2 | 2015 | 199 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 1341 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 118 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5566 | 0.050 |
Why?
|
| Philadelphia | 1 | 2002 | 36 | 0.050 |
Why?
|
| Microbubbles | 1 | 2022 | 17 | 0.050 |
Why?
|
| Electronics | 1 | 2002 | 63 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 912 | 0.050 |
Why?
|
| Ear Canal | 1 | 2002 | 30 | 0.050 |
Why?
|
| Acoustics | 1 | 2022 | 40 | 0.050 |
Why?
|
| Radiometry | 2 | 2018 | 1017 | 0.050 |
Why?
|
| Odorants | 1 | 2002 | 80 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2023 | 378 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2005 | 291 | 0.050 |
Why?
|
| Ear Neoplasms | 1 | 2002 | 62 | 0.050 |
Why?
|
| Macromolecular Substances | 3 | 1998 | 340 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 3396 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 3413 | 0.050 |
Why?
|
| Particle Accelerators | 1 | 2024 | 362 | 0.050 |
Why?
|
| Choristoma | 1 | 2001 | 87 | 0.050 |
Why?
|
| Patient Readmission | 3 | 2015 | 581 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1556 | 0.050 |
Why?
|
| Arteries | 1 | 2022 | 289 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Disease Management | 2 | 2017 | 1105 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2058 | 0.050 |
Why?
|
| Risk | 1 | 2005 | 1943 | 0.050 |
Why?
|
| Echo-Planar Imaging | 1 | 2021 | 74 | 0.050 |
Why?
|
| Computational Biology | 2 | 2019 | 1280 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 311 | 0.040 |
Why?
|
| Automation | 1 | 2020 | 153 | 0.040 |
Why?
|
| Drainage | 1 | 2022 | 451 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 183 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 481 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 495 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2019 | 42 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2017 | 1574 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 327 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 69 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 2 | 1998 | 162 | 0.040 |
Why?
|
| Length of Stay | 3 | 2015 | 2010 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 1065 | 0.040 |
Why?
|
| Interleukin-9 | 1 | 1998 | 37 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2022 | 914 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 742 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 191 | 0.040 |
Why?
|
| Erythrocytes | 1 | 1999 | 336 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 71 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 162 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 92 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 1559 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2023 | 1193 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 1998 | 79 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2019 | 246 | 0.040 |
Why?
|
| Glossectomy | 2 | 2008 | 43 | 0.040 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2017 | 47 | 0.040 |
Why?
|
| Bacteria | 1 | 2002 | 654 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2018 | 225 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2011 | 592 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 293 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 179 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 318 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 282 | 0.040 |
Why?
|
| Time | 1 | 2017 | 184 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 1997 | 49 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2018 | 282 | 0.040 |
Why?
|
| Skin Transplantation | 2 | 2008 | 184 | 0.040 |
Why?
|
| Receptors, Interleukin-4 | 1 | 1996 | 21 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 364 | 0.030 |
Why?
|
| Survivorship | 1 | 2017 | 116 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 361 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1999 | 711 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 670 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 587 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2018 | 256 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 552 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2017 | 182 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 562 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 313 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1996 | 1646 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 1291 | 0.030 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1996 | 144 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2018 | 734 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2017 | 235 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 31 | 0.030 |
Why?
|
| Analog-Digital Conversion | 1 | 2015 | 5 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 1996 | 72 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 499 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 218 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 729 | 0.030 |
Why?
|
| Cell Polarity | 1 | 1997 | 214 | 0.030 |
Why?
|
| Drug Industry | 1 | 2016 | 89 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 210 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 527 | 0.030 |
Why?
|
| Enzymes | 1 | 2015 | 71 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2016 | 125 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1578 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1279 | 0.030 |
Why?
|
| Acute Disease | 1 | 2000 | 2501 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 293 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 354 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2016 | 96 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3621 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1997 | 604 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 637 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 453 | 0.030 |
Why?
|
| Perfusion | 1 | 2016 | 285 | 0.030 |
Why?
|
| Phototherapy | 1 | 2015 | 83 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 2015 | 89 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 491 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 784 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 220 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 311 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 563 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 659 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1997 | 1258 | 0.030 |
Why?
|
| Orbit Evisceration | 1 | 2013 | 47 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 719 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 629 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 1997 | 1427 | 0.030 |
Why?
|
| Nasolacrimal Duct | 1 | 2013 | 45 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 263 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 730 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 4493 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1058 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 773 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 3455 | 0.030 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2012 | 10 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2199 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1250 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1847 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2014 | 629 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2012 | 41 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 5252 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 612 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 567 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 1051 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2013 | 938 | 0.020 |
Why?
|
| Kidney | 1 | 2021 | 2251 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 962 | 0.020 |
Why?
|
| Temporal Arteries | 1 | 2011 | 43 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 323 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 970 | 0.020 |
Why?
|
| Molecular Sequence Data | 5 | 1996 | 6706 | 0.020 |
Why?
|
| Gene Expression | 2 | 1998 | 3658 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 807 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 654 | 0.020 |
Why?
|
| Medicare | 1 | 2016 | 932 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 100 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1823 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1996 | 1219 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1995 | 1145 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 105 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 134 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 2588 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1996 | 5740 | 0.020 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2010 | 46 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 157 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 217 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2020 | 2761 | 0.020 |
Why?
|
| Reoperation | 1 | 2015 | 1393 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 297 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 968 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1466 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 670 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 832 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2010 | 161 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 2357 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 206 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1204 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 2594 | 0.020 |
Why?
|
| Dasatinib | 1 | 2013 | 881 | 0.020 |
Why?
|
| Amino Acid Sequence | 4 | 1996 | 4582 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 496 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1249 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2011 | 348 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2013 | 860 | 0.020 |
Why?
|
| Triazines | 1 | 2010 | 124 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 723 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1550 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1289 | 0.020 |
Why?
|
| Lip | 1 | 2008 | 35 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 467 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 759 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 222 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1993 | 0.020 |
Why?
|
| Cytokines | 1 | 1997 | 2825 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1206 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 1029 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 709 | 0.020 |
Why?
|
| Software | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1035 | 0.020 |
Why?
|
| Fibula | 1 | 2008 | 152 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 4882 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2459 | 0.020 |
Why?
|
| DNA | 1 | 1995 | 3055 | 0.020 |
Why?
|
| Bone Plates | 1 | 2006 | 49 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2006 | 68 | 0.020 |
Why?
|
| Staff Development | 1 | 2006 | 62 | 0.020 |
Why?
|
| Microsurgery | 1 | 2008 | 235 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1831 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 196 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2006 | 120 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2010 | 657 | 0.020 |
Why?
|
| Child | 2 | 2023 | 30545 | 0.020 |
Why?
|
| Phosphotyrosine | 2 | 1995 | 125 | 0.020 |
Why?
|
| Personnel Selection | 1 | 2006 | 87 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 3850 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 800 | 0.020 |
Why?
|
| Laminin | 1 | 2005 | 212 | 0.020 |
Why?
|
| Career Choice | 1 | 2006 | 209 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 1995 | 632 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 279 | 0.010 |
Why?
|
| Pain | 1 | 2012 | 1698 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 635 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2006 | 309 | 0.010 |
Why?
|
| Tympanoplasty | 1 | 2002 | 12 | 0.010 |
Why?
|
| Audiometry | 1 | 2002 | 26 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4157 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 3038 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 2104 | 0.010 |
Why?
|
| Hypoxia | 1 | 2005 | 473 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 729 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 6595 | 0.010 |
Why?
|
| Hospital Charges | 1 | 2002 | 88 | 0.010 |
Why?
|
| Temporal Bone | 1 | 2002 | 109 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 3662 | 0.010 |
Why?
|
| Health Resources | 1 | 2002 | 171 | 0.010 |
Why?
|
| Curriculum | 1 | 2006 | 909 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2006 | 1347 | 0.010 |
Why?
|
| Biopolymers | 1 | 1999 | 37 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 1187 | 0.010 |
Why?
|
| Receptors, Interleukin-9 | 1 | 1998 | 3 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1999 | 288 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1998 | 141 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 418 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1998 | 166 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 2484 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 3537 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1998 | 220 | 0.010 |
Why?
|
| Retroviridae | 1 | 1998 | 373 | 0.010 |
Why?
|
| Protein Multimerization | 1 | 1998 | 232 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1998 | 520 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 192 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 804 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 1436 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1509 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1995 | 1728 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1995 | 682 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1995 | 1316 | 0.010 |
Why?
|
| Infant | 1 | 2001 | 13969 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 3942 | 0.000 |
Why?
|